Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Furiex Pharmaceuticals, Inc
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has a diagnosis of IBS by Rome III criteria with a subtype of diarrhea
Female patients must be:
postmenopausal, defined as amenorrhea for at least 2 years at Prescreening,
surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
abstinent, or
if sexually active, be practicing an effective method of birth control.
You may not be if
Patient has a diagnosis of IBS by Rome III criteria with a subtype of constipation, mixed IBS, or unsubtyped IBS
Patient has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease
Patient has a history of diverticulitis within 6 months prior to Prescreening
Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, impaired intestinal circulation (eg, aortoiliac disease), thrombophlebitis of a major vein, or hypercoagulable states.
Other protocol-specific eligibility criteria may apply.
Clareo Health | Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
